Monday, December 10, 2018

Teva Pharmaceuticals last week launched...

...its generic version of Mylan's EpiPen. Though the new generic was lauded as a lower-cost option by the FDA, it launched with the same list price as EpiPen — $300. Mylan's EpiPen holds preferred-tier formulary status for 52% of covered lives, and is not covered for 16% of lives. 

No comments:

Post a Comment